Close Menu

phase II clinical study

The Phase II study will assess the antibody-drug conjugate patritumab deruxtecan for previously treated colorectal cancer patients expressing varying levels of HER3.

The trial, which received positive feedback from the FDA, will enroll patients who have a biomarker that may increase their chances of responding to the drug.

The CheckMate-650 trial showed the potential of combined immunotherapy in metastatic, castration-resistant prostate cancer and identified subgroups for further study.  

The biopharma company is evaluating its experimental immunotherapy against HPV-positive cancers alone and in combination with a bifunctional fusion protein.

The trial will use Natera's Signatera test to determine patient enrollment eligibility based on the presence of ctDNA and to evaluate response based on ctDNA clearance.

The first prospective study of BRAF-mutated cholangiocarcinoma showed a 51 percent response rate among patients treated with Novartis' Tafinlar and Mekinist.

Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.

Patients on the combo regimen had similar outcomes to those on monotherapy, but researchers said that the benefit seen in certain groups should be explored in randomized trials.

The trial will assess patients' blood samples to determine DSP107's effect on T-cells, B-cells, NK cells, and monocytes and their expression of activation markers.

Caris will use its suite of technologies to help Elevation Oncology enroll patients with NRG1 fusion-positive solid tumors to its Phase II trial of seribantumab.